PPARG and atherosclerosis: Accordingly, the treatment with 5-aza-2-deoxycytidine (decitabine), a recognized inhibitor of DNMTs, results in an increased M2 polarization induced by the inhibition of the PPAR-γ promoter, which in turn prevents obesity-induced inflammation, atherosclerosis, and insulin resistance [37, 38].